No abstract

No abstract

Background: In the Netherlands, limited variability exists in the performance of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) among centers treating colorectal peritoneal metastases (PM), except for the intraperitoneal drug administration. This study offers a unique opportunity to investigate any disparities in survival between the two most frequently used HIPEC regimens worldwide: mitomycin C (MMC) and oxaliplatin.

A479the 6 new oncology drugs reimbursed by AIFA in 2014 with average times from the national reimbursement decision to the regional one ranging from 3 months in Piemonte to 5 months in Emilia Romagna. The Lazio and Sardinia Regions have evaluated only 1 out of the 6 drugs with an access time of around 2.5 and 6 months, respectively. ConClusions: In Italy, the average times from the national reimbursement decisions to the regional evaluations aiming to the formulary inclusion vary widely between Regions.

No abstract